FDA Grants RMAT Designation to United Therapeutics' miroliverELAP for Acute Liver Failure — United Therapeutics Corporation

Event summary

FDA granted RMAT designation to miroliverELAP, an external liver assist product for acute liver failure (ALF).
miroliverELAP uses a bioengineered liver created from decellularized porcine liver scaffolds and human cells.
Positive phase 1 study results announced in January 2026; full results to be published in H2 2026.
RMAT designation accelerates development and regulatory review for regenerative medicine therapies.

The big picture

United Therapeutics' RMAT designation for miroliverELAP underscores the FDA's focus on accelerating regenerative medicine therapies for critical unmet needs. The designation provides significant regulatory advantages, potentially shortening the time to market for miroliverELAP, a product addressing the severe shortage of transplantable organs for ALF patients. This move aligns with broader industry trends toward bioengineered organ alternatives and regenerative therapies.

What we're watching

Regulatory Advantage: How RMAT designation will accelerate miroliverELAP's path to market and reduce development timelines.
Clinical Validation: Whether the full phase 1 study results will confirm miroliverELAP's efficacy and safety in ALF patients.
Competitive Positioning: The pace at which United Therapeutics can advance miroliverELAP and mirokidney through its pipeline, given the RMAT designation.